ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Adamis Provides Update on Zimhi drugs
June 21, 2021Adamis Pharmaceuticals Corporation today announced that the FDA has accepted for review the Company’s resubmitted New Drug Application (NDA) for ZIMHI?, which is its higher naloxone injection product candidate for the treatment of opioid overdose.
Pharma Sources Insight January 2025
